Dilute activated partial thromboplastin time (dAPTT)
Kaolin clotting time (KCT)
Silica clotting time (SCT)
Isolated or combined deficiencies of coagulation factors II, V, VIII, IX, X, XI, XII, prekallikrein (PK), and high molecular weight kininogen (HMWK)
Fibrinogen deficiencies
Non-phospholipid-dependent inhibitors
Therapeutic anticoagulation with vitamin K antagonist (VKA), unfractionated heparin (UFH), low molecular weight heparin (LMWH), direct thrombin inhibitor (DTI), and direct FXa inhibitor (DFXaI)
Based on the extrinsic pathway
Dilute prothrombin time (dPT)
Activated Seven Lupus Anticoagulant (ASLA) assay
Isolated or combined deficiencies of coagulation factors II, V, X; also factor VII for dPT
Fibrinogen deficiencies
Non-phospholipid-dependent inhibitors
Therapeutic anticoagulation with VKA, DTI, and DFXaI
Therapeutic anticoagulation with UFH & LMWH if neutraliser capacity exceeded
Based on the common pathway (FX activation)
dRVVT
Vipera lebetina venom time (VLVT)
Isolated or combined deficiencies of coagulation factors II, V, and X
Fibrinogen deficiencies
Non-phospholipid-dependent inhibitors
Therapeutic anticoagulation with VKA, DTI, and DFXaI
Therapeutic anticoagulation with UFH & LMWH if neutraliser capacity exceeded
Based on the common pathway (FII activation)
Taipan snake venom time (TSVT)
Textarin time
Factor II deficiency; also factor V for textarin time
Fibrinogen deficiencies
Non-phospholipid-dependent inhibitors
Therapeutic anticoagulation with UFH, LMWH, and DTI
Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML, et al.; New APS Classification Criteria Collaborators. Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria.Arthritis Care Res (Hoboken). 2021;73:1490–501. [DOI] [PubMed] [PMC]
McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).Proc Natl Acad Sci U S A. 1990;87:4120–4. [DOI] [PubMed] [PMC]
Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.Lancet. 1990;335:1544–7. [DOI] [PubMed]
Meroni PL, Borghi MO. Antiphospholipid antibody assays in 2021: looking for a predictive value in addition to a diagnostic one.Front Immunol. 2021;12:726820. [DOI] [PubMed] [PMC]
Misasi R, Capozzi A, Longo A, Recalchi S, Lococo E, Alessandri C, et al. “New” antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome.J Immunol Res. 2015;2015:858542. [DOI] [PubMed] [PMC]
Misasi R, Longo A, Recalchi S, Caissutti D, Riitano G, Manganelli V, et al. Molecular mechanisms of “antiphospholipid antibodies” and their paradoxical role in the pathogenesis of “Seronegative APS”.Int J Mol Sci. 2020;21:8411. [DOI] [PubMed] [PMC]
Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH.J Thromb Haemost. 2018;16:809–13. [DOI] [PubMed]
Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.J Thromb Haemost. 2010;8:237–42. [DOI] [PubMed]
Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study.Blood. 2011;118:4714–8. [DOI] [PubMed]
Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.Lupus. 2014;23:1468–76. [DOI] [PubMed]
Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, et al.; Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study.Ann Rheum Dis. 2011;70:1083–6. [DOI] [PubMed]
Yin D, de Groot PG, Ninivaggi M, Devreese KMJ, de Laat B. Clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome.Thromb Haemost. 2021;121:1220–7. [DOI] [PubMed]
Qi W, Zhao J, Huang C, Jiang N, Li J, Wu C, et al. Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study.Arthritis Res Ther. 2022;24:140. [DOI] [PubMed] [PMC]
Moore GW. Testing for lupus anticoagulants.Semin Thromb Hemost. 2022;48:643–60. [DOI] [PubMed]
Noordermeer T, Molhoek JE, Schutgens REG, Sebastian SAE, Drost-Verhoef S, van Wesel ACW, et al. Anti-β2-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action.J Thromb Haemost. 2021;19:1018–28. [DOI] [PubMed] [PMC]
Moore GW. Commonalities and contrasts in recent guidelines for lupus anticoagulant detection.Int J Lab Hematol. 2014;36:364–73. [DOI] [PubMed]
Tripodi A, Cohen H, Devreese KMJ. Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis.J Thromb Haemost. 2020;18:1569–75. [DOI] [PubMed]
Moore GW. Alternative assays to dRVVT and aPTT for lupus anticoagulant detection.Am J Hematol. 2020;95:992–8. [DOI] [PubMed]
Keeling D, Mackie I, Moore GW, Greer IA, Greaves M; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome.Br J Haematol. 2012;157:47–58. [DOI] [PubMed]
Clinical and Laboratory Standards Institute (CLSI). Laboratory testing for the lupus anticoagulant; approved guideline. Wayne: Clinical and Laboratory Standards Institute; 2014.
Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation.J Thromb Haemost. 2020;18:2828–39. [DOI] [PubMed]
Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces.Thromb Haemost. 1998;79:79–86. [PubMed]
Field SL, Chesterman CN, Dai YP, Hogg PJ. Lupus antibody bivalency is required to enhance prothrombin binding to phospholipid.J Immunol. 2001;166:6118–25. [DOI] [PubMed]
Kelsey PR, Stevenson KJ, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time--the central role of phosphatidyl serine.Thromb Haemost. 1984;52:172–5. [PubMed]
Stevenson KJ, Seddon JM. The role of lipids in the detection of lupus anticoagulant by the dilute Russell Viper venom test: are platelets or reagents containing hexagonal HII phases necessary?Br J Haematol. 1994;86:583–9. [DOI] [PubMed]
Okuda M, Yamamoto Y. Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference.Clin Lab Haematol. 2004;26:215–23. [DOI] [PubMed]
Kristoffersen AH, Hammer IJ, Vannes S, Åsberg A, Aakre KM. Impact of different preanalytical conditions on results of lupus anticoagulant tests.Int J Lab Hematol. 2019;41:745–53. [DOI] [PubMed]
Cohen H, Mackie IJ, Devreese KMJ; International Society for Thrombosis and Haemostasis Scientific and Standardization Committee for Lupus Anticoagulant/Antiphospholipid Antibodies. Clinical and laboratory practice for lupus anticoagulant testing: an International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey.J Thromb Haemost. 2019;17:1715–32. [DOI] [PubMed]
Sletnes KE, Gravem K, Wisløff F. Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies.Thromb Res. 1992;66:43–53. [DOI] [PubMed]
Adcock DM, Moore GW, Montalvão SL, Kershaw G, Gosselin RC. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art.Semin Thromb Hemost. 2022;[Epub ahead of print]. [DOI] [PubMed]
Moore GW, Savidge GF, Smith MP. Improved detection of lupus anticoagulants by the dilute Russell’s Viper venom time.Blood Coagul Fibrinolysis. 2000;11:767–74. [DOI] [PubMed]
Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al.; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.J Thromb Haemost. 2009;7:1737–40. [DOI] [PubMed]
Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants.Semin Thromb Hemost. 2014;40:163–71. [DOI] [PubMed]
Moore GW. Clinical utility of the less commonly employed assays for lupus anticoagulant detection: the evidence.J Coag Dis. 2010;2:69–79.
Moore GW. Current controversies in lupus anticoagulant detection.Antibodies (Basel). 2016;5:22. [DOI] [PubMed] [PMC]
Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI. Lupus anticoagulant testing: performance and practices by north american clinical laboratories.Am J Clin Pathol. 2010;134:764–73. [DOI] [PubMed]
Adams M. Measurement of lupus anticoagulants: an update on quality in laboratory testing.Semin Thromb Hemost. 2013;39:267–71. [DOI] [PubMed]
Lawrie AS, Mackie IJ, Purdy G, Machin SJ. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers.Thromb Haemost. 1999;81:758–62. [PubMed]
Moore GW, Savidge GF. Heterogeneity of Russell’s viper venom affects the sensitivity of the dilute Russell’s viper venom time to lupus anticoagulants.Blood Coagul Fibrinolysis. 2004;15:279–82. [DOI] [PubMed]
McGlasson DL, Fritsma GA. Comparison of six dilute Russell viper venom time lupus anticoagulant screen/confirm assay kits.Semin Thromb Hemost. 2013;39:315–9. [DOI] [PubMed]
Fritsma GA, Dembitzer FR, Randhawa A, Marques MB, Van Cott EM, Adcock-Funk D, et al. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.Am J Clin Pathol. 2012;137:904–8. [DOI] [PubMed]
Adcock DM, Marlar RA. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant.Arch Pathol Lab Med. 1992;116:837–40. [PubMed]
Liestøl S, Jacobsen EM, Wisløff F. Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin.Thromb Res. 2002;105:177–82. [DOI] [PubMed]
Mackie IJ, Lawrie AS, Greenfield RS, Guinto ER, Machin SJ. A new lupus anticoagulant test based on dilute prothrombin time.Thromb Res. 2004;114:673–4.
Moore GW, Smith MP, Patel Y, Savidge GF. The Activated Seven Lupus Anticoagulant (ASLA) assay: a new test for lupus anticoagulants (LAs). Evidence that some LAs are detectable only in extrinsic pathway-based assays.Blood Coagul Fibrinolysis. 2002;13:261–9. [DOI] [PubMed]
Martinuzzo M, Adamczuk Y, Varela ML, Pombo G, Forastiero R. The Activated Seven Lupus Anticoagulant (ASLA) test has comparable sensitivity to classical assays for screening of lupus anticoagulant.Thromb Haemost. 2005;93:1007–9. [PubMed]
Triplett DA, Stocker KF, Unger GA, Barna LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants.Thromb Haemost. 1993;70:925–31. [PubMed]
Rooney AM, McNally T, Mackie IJ, Machin SJ. The Taipan snake venom time: a new test for lupus anticoagulant.J Clin Pathol. 1994;47:497–501. [DOI] [PubMed] [PMC]
Moore GW, Culhane AP, Maloney JC, Archer RA, Breen KA, Hunt BJ. Taipan snake venom time coupled with ecarin time enhances lupus anticoagulant detection in nonanticoagulated patients.Blood Coagul Fibrinolysis. 2016;27:477–80. [DOI] [PubMed]
Cunliffe A, Dobson J, Swallow G, Ravenscroft J, Tang TS. Taipan snake venom time for antiphospholipid syndrome solves a 20-year diagnostic challenge.Clin Exp Dermatol. 2020;45:805–8. [DOI] [PubMed]
Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns.Br J Haematol. 1978;40:143–51. [DOI] [PubMed]
Derksen RH, de Groot PG. Tests for lupus anticoagulant revisited.Thromb Res. 2004;114:521–6. [DOI] [PubMed]
Dragoni F, Minotti C, Palumbo G, Faillace F, Redi R, Bongarzoni V, et al. As compared to kaolin clotting time, silica clotting time is a specific and sensitive automated method for detecting lupus anticoagulant.Thromb Res. 2001;101:45–51. [DOI] [PubMed]
Chantarangkul V, Tripodi A, Arbini A, Mannucci PM. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants.Thromb Res. 1992;67:355–65. [DOI] [PubMed]
Grypiotis P, Ruffatti A, Pengo V, Tonello M, Biasiolo A, Zamboni D, et al. Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome.J Clin Lab Anal. 2006;20:15–8. [DOI] [PubMed] [PMC]
Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant.Blood. 1976;48:499–509. [PubMed]
Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure.Am J Clin Pathol. 1983;79:678–82. [DOI] [PubMed]
Nakai K, Wada H, Nakatani K, Kamikura Y, Mastumoto T, Kobayashi T, et al. Usefulness of a diluted prothrombin time for accurately diagnosing antiphospholipid syndrome.Vac Dis Prev. 2009;6:25–9.
Liu HW, Wong KL, Lin CK, Wong WS, Tse PW, Chan GT. The reappraisal of dilute tissue thromboplastin inhibition test in the diagnosis of lupus anticoagulant.Br J Haematol. 1989;72:229–34. [DOI] [PubMed]
Goudemand J, Caron C, De Prost D, Derlon A, Borg JY, Sampol J, et al. Evaluation of sensitivity and specificity of a standardized procedure using different reagents for the detection of lupus anticoagulants. The Working Group on Hemostasis of the Société Française de Biologie Clinique and for the Groupe d’Etudes sur I’Hémostase et la Thrombose.Thromb Haemost. 1997;77:336–42. [PubMed]
Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin.Br J Haematol. 1994;87:94–9. [DOI] [PubMed]
Swadzba J, Iwaniec T, Pulka M, De Laat B, De Groot PG, Musial J. Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines.J Thromb Haemost. 2011;9:1776–83. [DOI] [PubMed]
Goldford MD. Lupus anticoagulant screen and confirm reagents utilizing the FX activating venom from Vipera lebetina.J Thromb Haemost. 2013;11:61.
Moore GW. Snake venoms in diagnostic hemostasis and thrombosis.Semin Thromb Hemost. 2022;48:145–60. [DOI] [PubMed]
Moore GW, Smith MP, Savidge GF. The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants.Blood Coagul Fibrinolysis. 2003;14:307–12. [DOI] [PubMed]
Moore GW, Kamat AV, Gurney DA, O’Connor O, Rangarajan S, Carr R, et al. Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin’s lymphoma.Clin Lab Haematol. 2004;26:429–34. [DOI] [PubMed]
Forastiero RR, Cerrato GS, Carreras LO. Evaluation of recently described tests for detection of the lupus anticoagulant.Thromb Haemost. 1994;72:728–33. [PubMed]
Luddington R, Scales C, Baglin T. Lupus anticoagulant testing with optical end point automation.Thromb Res. 1999;96:197–203. [DOI] [PubMed]
Moore GW, Jones PO, Platton S, Hussain N, White D, Thomas W, et al. International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.J Thromb Haemost. 2021;19:3177–92. [DOI] [PubMed]
Devreese KM. Evaluation of a new commercial dilute prothrombin time in the diagnosis of lupus anticoagulants.Thromb Res. 2008;123:404–11. [DOI] [PubMed]
Galli M, Borrelli G, Jacobsen EM, Marfisi RM, Finazzi G, Marchioli R, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study.Blood. 2007;110:1178–83. [DOI] [PubMed]
Moore GW. Combining Taipan snake venom time/Ecarin time screening with the mixing studies of conventional assays increases detection rates of lupus anticoagulants in orally anticoagulated patients.Thromb J. 2007;5:12. [DOI] [PubMed] [PMC]
Krilis SA, Giannakopoulos B. Laboratory methods to detect antiphospholipid antibodies.Hematology Am Soc Hematol Educ Program. 2014;2014:321–8. [DOI] [PubMed]
Pradella P, Azzarini G, Santarossa L, Caberlotto L, Bardin C, Poz A, et al. Cooperation experience in a multicentre study to define the upper limits in a normal population for the diagnostic assessment of the functional lupus anticoagulant assays.Clin Chem Lab Med. 2013;51:379–85. [DOI] [PubMed]
Kaczor DA, Bickford NN, Triplett DA. Evaluation of different mixing study reagents and dilution effect in lupus anticoagulant testing.Am J Clin Pathol. 1991;95:408–11. [DOI] [PubMed]
Moore GW, Brown KL, Bromidge ES, Drew AJ, Ledford-Kraemer MR. Lupus anticoagulant detection: out of control?Int J Lab Hematol. 2013;35:128–36. [DOI] [PubMed]
Cabo J, Morimont L, Baudar J, Guldenpfennig M, Jacqmin H, Soleimani R, et al. Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing.Int J Lab Hematol. 2023;45:126–36. [DOI] [PubMed]
Poller L. International Normalized Ratios (INR): the first 20 years.J Thromb Haemost. 2004;2:849–60. [DOI] [PubMed]
Pennings MT, De Groot PG, Meijers JC, Huisman A, Derksen RH, Urbanus RT. Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma?Thromb Haemost. 2014;112:736–42. [DOI] [PubMed]
Moore GW, Maloney JC, de Jager N, Dunsmore CL, Gorman DK, Polgrean RF, et al. Application of different lupus anticoagulant diagnostic algorithms to the same assay data leads to interpretive discrepancies in some samples.Res Pract Thromb Haemost. 2017;1:62–8. [DOI] [PubMed] [PMC]
Gerbutavicius R, Fareed J, Messmore HL Jr, Iqbal O, Hoppensteadt DA, Wehrmacher WH, et al. Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell’s viper venom tests revisited.Clin Appl Thromb Hemost. 2002;8:115–24. [DOI] [PubMed]
Ling LQ, Liu CN, Huang XB, Liao J, Jia J, Zhou J. Interpretation of clot-based lupus anticoagulant assays-Normalizing clotting time against different denominators.Int J Lab Hematol. 2022;44:777–84. [DOI] [PubMed]
Moore GW. Reference interval mean clotting times should not be used to calculate lupus anticoagulant mixing test ratios unless they match the normal pooled plasma clotting time.Thromb Res. 2017;159:16–8.
Gardiner C, MacKie IJ, Malia RG, Jones DW, Winter M, Leeming D, et al. The importance of locally derived reference ranges and standardized calculation of dilute Russell’s viper venom time results in screening for lupus anticoagulant.Br J Haematol. 2000;111:1230–5. [DOI] [PubMed]
Tripodi A, Chantarangkul V, Cini M, Devreese K, Dlott JS, Giacomello R, et al. Variability of cut-off values for the detection of lupus anticoagulants: results of an international multicenter multiplatform study.J Thromb Haemost. 2017;15:1180–90. [DOI] [PubMed]
Moore GW, Kumano O. Lupus anticoagulant assay cut-offs vary between reagents even when derived from a common set of normal donor plasmas.J Thromb Haemost. 2020;18:439–44. [DOI] [PubMed]
Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline. 3rd ed. Wayne: Clinical and Laboratory Standards Institute; 2008.
Averina M, Johannesen S, Brox J. Diagnostic accuracy of silica clotting time method for lupus anticoagulant in a clinical population with various symptoms of antiphospholipid syndrome.Lupus. 2016;25:418–22. [DOI] [PubMed]
Kumano O, Ieko M, Naito S, Yoshida M, Takahashi N, Aoki T. Index of circulating anticoagulant cut-off value establishment in activated partial thromboplastin time mixing test for lupus anticoagulant diagnosis.J Thromb Haemost. 2013;11:1919–22. [DOI] [PubMed]
Chantarangkul V, Peyvandi F, Tripodi A; Investigating Group. Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants.Thromb Res. 2020;190:20–5. [DOI] [PubMed]
Chantarangkul V, Biguzzi E, Asti D, Palmucci C, Tripodi A. Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on Lupus Anticoagulant.Thromb Haemost. 2013;110:46–52. [DOI] [PubMed]
Kershaw G, Orellana D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times.Semin Thromb Hemost. 2013;39:283–90. [DOI] [PubMed]
Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity.Thromb Haemost. 1987;57:144–7. [PubMed]
Roussi J, Roisin JP, Goguel A. Lupus anticoagulants: first French interlaboratory Etalonorme survey.Am J Clin Pathol. 1996;105:788–93. [DOI] [PubMed]
Devreese KM. Interpretation of normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulants.Thromb Res. 2007;119:369–76. [DOI] [PubMed]
Depreter B, Devreese KM. Differences in lupus anticoagulant final conclusion through clotting time or Rosner index for mixing test interpretation.Clin Chem Lab Med. 2016;54:1511–6. [DOI] [PubMed]
Moore GW, Culhane AP, Daw CR, Noronha CP, Kumano O. Mixing test specific cut-off is more sensitive at detecting lupus anticoagulants than index of circulating anticoagulant.Thromb Res. 2016;139:98–101. [DOI] [PubMed]
Kumano O, Moore GW. Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test-specific cut-off than index of circulating anticoagulant.Res Pract Thromb Haemost. 2017;2:105–13. [DOI] [PubMed] [PMC]
Moore GW, Savidge GF. The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied.Thromb Res. 2006;118:523–8. [DOI] [PubMed]
Favaloro EJ. Coagulation mixing studies: utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests.Am J Hematol. 2020;95:117–28. [DOI] [PubMed]
Favaloro E. Mixing studies for lupus anticoagulant: mostly yes, sometimes no.Clin Chem Lab Med. 2020;58:487–91. [DOI] [PubMed]
Moore GW. Mixing studies for lupus anticoagulant: mostly no, sometimes yes.Clin Chem Lab Med. 2020;58:492–5. [DOI] [PubMed]
Reber G, Meijer P. In ECAT veritas?Lupus. 2012;21:722–4. [DOI] [PubMed]
Male C, Lechner K, Speiser W, Pabinger I. Transient lupus anticoagulants in children: stepwise disappearance of diagnostic features.Thromb Haemost. 2000;83:174–5. [PubMed]
Thom J, Ivey L, Eikelboom J. Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant.J Thromb Haemost. 2003;1:2689–91. [DOI] [PubMed]
Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation.Thromb Haemost. 1997;77:934–7. [PubMed]
Devreese KM, de Laat B. Mixing studies in lupus anticoagulant testing are required at least in some type of samples.J Thromb Haemost. 2015;13:1475–8. [DOI] [PubMed]
Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required.J Thromb Haemost. 2010;8:2828–31. [DOI] [PubMed]
Devreese KM. No more mixing tests required for integrated assay systems in the laboratory diagnosis of lupus anticoagulants?J Thromb Haemost. 2010;8:1120–2. [DOI] [PubMed]
Hong SK, Hwang SM, Kim JE, Kim HK. Clinical significance of the mixing test in laboratory diagnoses of lupus anticoagulant: the fate of the mixing test in integrated lupus anticoagulant test systems.Blood Coagul Fibrinolysis. 2012;23:739–44. [DOI] [PubMed]
Chandrashekar V. Dilute Russell’s viper venom and activated partial thromboplastin time in lupus anticoagulant diagnosis: is mixing essential?Blood Coagul Fibrinolysis. 2016;27:408–11. [DOI] [PubMed]
Asakrah S, Davis R, Bhargava P. Practical considerations and testing nuances for the detection of lupus anticoagulant: do low phospholipid screen results, assay type, and test ratio matter?Am J Clin Pathol. 2021;156:1073–82. [DOI] [PubMed]
Jacobsen EM, Wisløff F. False negative screening tests for lupus anticoagulants —an unrecognized problem?Thromb Res. 1996;82:445–51. [DOI] [PubMed]
Moore GW, Henley A, Greenwood CK, Rangarajan S. Further evidence of false negative screening for lupus anticoagulants.Thromb Res. 2008;121:477–84. [DOI] [PubMed]
Reda S, Brügelmann A, Müller J, Oldenburg J, Pötzsch B, Rühl H. Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants.Sci Rep. 2020;10:12221. [DOI] [PubMed] [PMC]
Tripodi A. Diagnostic challenges on the laboratory detection of lupus anticoagulant.Biomedicines. 2021;9:844. [DOI] [PubMed] [PMC]
Olteanu H, Downes KA, Patel J, Praprotnik D, Sarode R. Warfarin does not interfere with lupus anticoagulant detection by dilute Russell’s viper venom time.Clin Lab. 2009;55:138–42. [PubMed]
Pengo V, Zardo L, Cattini MG, Bison E, Pontara E, Altinier S, et al. Prothrombin is responsible for the lupus cofactor phenomenon in a patient with lupus anticoagulant/hypoprothrombinemia syndrome.TH Open. 2020;4:e40–4. [DOI] [PubMed] [PMC]
Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I.Thromb Haemost. 1992;67:499–502. [PubMed]
Murphy CH, Jin J, Zehnder JL. Antiphospholipid antibodies in patients with lupus anticoagulant prozone effect.Am J Clin Pathol. 2020;153:229–34. [DOI] [PubMed]
Mackman N. Triggers, targets and treatments for thrombosis.Nature. 2008;451:914–8. [DOI] [PubMed] [PMC]
Zuily S, Cohen H, Isenberg D, Woller SC, Crowther M, Dufrost V, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.J Thromb Haemost. 2020;18:2126–37. [DOI] [PubMed]
Giarretta I, Ageno W, Dentali F. Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome.Haematologica. 2022;107:2737–41. [DOI] [PubMed] [PMC]
Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA.Thromb Haemost. 2002;88:583–6. [PubMed]
Jouhikainen T. Detection of lupus anticoagulant by means of dilute Russell’s viper venom time is affected by oral anticoagulant therapy.Blood Coagul Fibrinolysis. 1990;1:627–32. [PubMed]
Chandler JB, Torres R, Rinder HM, Tormey CA. Lupus anticoagulant testing and anticoagulation do not mix: quantitation of discrepant results and potential approaches to reduce false positives.Br J Haematol. 2014;167:704–7. [DOI] [PubMed]
Seheult JN, Meyer MP, Bontempo FA, Chibisov I. The effects of indirect- and direct-acting anticoagulants on lupus anticoagulant assays: a large, retrospective study at a coagulation reference laboratory.Am J Clin Pathol. 2017;147:632–40. [DOI] [PubMed]
Kanouchi K, Narimatsu H, Ohnuma O, Morikane K, Fukao A. Clinical usefulness of the dilute Russell viper venom time test for patients taking warfarin.Int J Hematol. 2017;106:206–11. [DOI] [PubMed]
Isert M, Miesbach W, Stoever G, Lindhoff-Last E, Linnemann B. Screening for lupus anticoagulants in patients treated with vitamin K antagonists.Int J Lab Hematol. 2015;37:758–65. [DOI] [PubMed]
Moore GW, Peyrafitte M, Dunois C, Amiral J. Newly developed dilute Russell’s viper venom reagents for lupus anticoagulant detection with improved specificity.Lupus. 2018;27:95–104. [DOI] [PubMed]
Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors.Pathophysiol Haemost Thromb. 2004;33:173–83. [DOI] [PubMed]
Kini RM, Koh CY. Metalloproteases affecting blood coagulation, fibrinolysis and platelet aggregation from snake venoms: definition and nomenclature of interaction sites.Toxins (Basel). 2016;8:284. [DOI] [PubMed] [PMC]
De Kesel PMM, Devreese KMJ. The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: can activated carbon eliminate false-positive results?Res Pract Thromb Haemost. 2019;4:161–8. [DOI] [PubMed] [PMC]
Kitchen S, Cartwright I, Woods TA, Jennings I, Preston FE. Lipid composition of seven APTT reagents in relation to heparin sensitivity.Br J Haematol. 1999;106:801–8. [DOI] [PubMed]
Beyazit F, Ünal Çetin E, Beyazit Y. False-positive results of lupus anticoagulant tests should be kept in mind in pregnant patients receiving low molecular weight heparin.J Turk Ger Gynecol Assoc. 2021;22:334–5. [DOI] [PubMed] [PMC]
Martinuzzo ME, Barrera LH, D ’adamo MA, Otaso JC, Gimenez MI, Oyhamburu J. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin.Int J Lab Hematol. 2014;36:144–50. [DOI] [PubMed]
Olah Z, Szarvas M, Bereczky Z, Kerenyi A, Kappelmayer J, Boda Z. Direct thrombin inhibitors and factor Xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.Arch Pathol Lab Med. 2013;137:967–73. [DOI] [PubMed]
Genzen JR, Miller JL. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing.Am J Clin Pathol. 2005;124:586–93. [DOI] [PubMed]
Gosselin RC, King JH, Janatpur KA, Dager WH, Larkin EC, Owings JT. Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing.Arch Pathol Lab Med. 2004;128:1142–5. [DOI] [PubMed]
Antovic A, Norberg EM, Berndtsson M, Rasmuson A, Malmström RE, Skeppholm M, et al. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.Thromb Haemost. 2017;117:1700–4. [DOI] [PubMed]
Hillarp A, Strandberg K, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Lindahl TL. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.Scand J Clin Lab Invest. 2018;78:575–83. [DOI] [PubMed]
Arachchillage DR, Mackie IJ, Efthymiou M, Isenberg DA, Machin SJ, Cohen H. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.J Thromb Haemost. 2015;13:1264–73. [DOI] [PubMed]
Gay J, Duchemin J, Imarazene M, Fontenay M, Jourdi G. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: a real-life study.Int J Lab Hematol. 2019;41:738–44. [DOI] [PubMed]
Hillarp A, Strandberg K, Gustafsson KM, Lindahl TL. Unveiling the complex effects of direct oral anticoagulants on dilute Russell’s viper venom time assays.J Thromb Haemost. 2020;18:1866–73. [DOI] [PubMed]
Ratzinger F, Lang M, Belik S, Jilma-Stohlawetz P, Schmetterer KG, Haslacher H, et al. Lupus-anticoagulant testing at NOAC trough levels.Thromb Haemost. 2016;116:235–40. [DOI] [PubMed]
Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.Pathology. 2016;48:60–71. [DOI] [PubMed]
Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M. Simple method for removing DOACs from plasma samples.Thromb Res. 2018;163:117–22. [DOI] [PubMed]
Cox-Morton S, MacDonald S, Thomas W. A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove.Br J Haematol. 2019;187:377–85. [DOI] [PubMed]
Farkh C, Ellouze S, Gounelle L, Sad Houari M, Duchemin J, Proulle V, et al. A diagnostic solution for lupus anticoagulant testing in patients taking direct oral FXa inhibitors using DOAC Filter.Front Med (Lausanne). 2021;8:683357. [DOI] [PubMed] [PMC]
Exner T, Ahuja M, Ellwood L. Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants.Clin Chem Lab Med. 2019;57:690–6. [DOI] [PubMed]
Riva N, Vella K, Hickey K, Gatt P, Grima C, Zammit D, et al. The effect of DOAC-Stop® on several oral and parenteral anticoagulants.Int J Lab Hematol. 2021;43:O171–5. [DOI] [PubMed]
Skaugen JM, Sayre C, Hassett AC, Chibisov I, Bontempo F, Meyer MP, et al. Performance characteristics of DOAC-Remove for neutralization of the effects of apixaban and rivaroxaban in lupus anticoagulant assays.Am J Clin Pathol. 2022;157:457–69. [DOI] [PubMed]
De Kesel PM, Devreese KMJ. Direct oral anticoagulant adsorption: impact on lupus anticoagulant testing-review of the literature and evaluation on spiked and patient samples.J Thromb Haemost. 2020;18:2003–17. [DOI] [PubMed]
Baker SA, Jin J, Pfaffroth C, Vu T, Zehnder JL. DOAC-Stop in lupus anticoagulant testing: direct oral anticoagulant interference removed in most samples.Res Pract Thromb Haemost. 2021;5:314–25. [DOI] [PubMed] [PMC]
Platton S, Hunt C. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.Int J Lab Hematol. 2019;41:227–33.
Tripodi A, Scalambrino E, Chantarangkul V, Paoletti O, Clerici M, Novembrino C, et al. Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection.Thromb Res. 2021;204:32–9. [DOI] [PubMed]
Dunois C, Peyrafitte M, De Muynck S, Villedieu V, Amiral J. New dRVVT assays for lupus anticoagulant (LA) detection with improved specificity and sensitivity: HEMOCLOT LA-S and LA-C.Res Pract Thromb Haemost. 2018;2:207.
Depreter B, Devreese KM. Dilute Russell’s viper venom time reagents in lupus anticoagulant testing: a well-considered choice.Clin Chem Lab Med. 2017;55:91–101. [DOI] [PubMed]
Arachchillage DRJ, Gomez K, Alikhan R, Anderson JAM, Lester W, Laffan M; British Society for Haematology Haemostasis and Thrombosis Taskforce. Addendum to British Society for Haematology guidelines on investigation and management of antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47–58): use of direct acting oral anticoagulants.Br J Haematol. 2020;189:212–5. [DOI] [PubMed]
Schouwers SM, Delanghe JR, Devreese KM. Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?Thromb Res. 2010;125:102–4. [DOI] [PubMed]
Ten Boekel E, Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C.Pathophysiol Haemost Thromb. 2002;32:137–42. [DOI] [PubMed]
Sørensen B, Ingerslev J. Dynamic APTT parameters: applications in thrombophilia.J Thromb Haemost. 2012;10:244–50. [DOI] [PubMed]
Tanaka KA, Bharadwaj S, Hasan S, Judd M, Abuelkasem E, Henderson RA, et al. Elevated fibrinogen, von Willebrand factor, and Factor VIII confer resistance to dilutional coagulopathy and activated protein C in normal pregnant women.Br J Anaesth. 2019;122:751–9. [DOI] [PubMed]
Walker GE, Merlin S, Zanolini D, Vandoni A, Volpe A, Gaidano G, et al. Factor VIII as a potential player in cancer pathophysiology.J Thromb Haemost. 2022;20:648–60. [DOI] [PubMed] [PMC]
Topping J, Quenby S, Farquharson R, Malia R, Greaves M. Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome.Hum Reprod. 1999;14:224–8. [DOI] [PubMed]
Yelnik CM, Porter TF, Branch DW, Laskin CA, Merrill JT, Guerra MM, et al. Brief report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes.Arthritis Rheumatol. 2016;68:1964–9. [DOI] [PubMed] [PMC]
von Landenberg P, Döring Y, Modrow S, Lackner KJ. Are antiphospholipid antibodies an essential requirement for an effective immune response to infections?Ann N Y Acad Sci. 2007;1108:578–83. [DOI] [PubMed]
Asherson RA, Cervera R. Antiphospholipid antibodies and infections.Ann Rheum Dis. 2003;62:388–93. [DOI] [PubMed] [PMC]
Shimura H, Imai Y, Ieko M, Shiseki M, Mori N, Teramura M, et al. Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis.Ann Hematol. 2013;92:143–4. [DOI] [PubMed]
Rodríguez-Pintó I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, et al.; CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry.Autoimmun Rev. 2016;15:1120–4. [DOI] [PubMed]
Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A.Eur J Haematol. 2015;94:38–44. [DOI] [PubMed]
Cooper PC, Pavlova A, Moore GW, Hickey KP, Marlar RA. Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH.J Thromb Haemost. 2020;18:271–7. [DOI] [PubMed]
Marlar RA, Gausman JN, Tsuda H, Rollins-Raval MA, Brinkman HJM. Recommendations for clinical laboratory testing for protein S deficiency: communication from the SSC committee plasma coagulation inhibitors of the ISTH.J Thromb Haemost. 2021;19:68–74. [DOI] [PubMed]
Karimi M, Peyvandi F, Naderi M, Shapiro A. Factor XIII deficiency diagnosis: challenges and tools.Int J Lab Hematol. 2018;40:3–11. [DOI] [PubMed]
